CytomX Therapeutics, Inc.
General ticker "CTMX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $624.6M (TTM average)
CytomX Therapeutics, Inc. follows the US Stock Market performance with the rate: 3.1%.
Estimated limits based on current volatility of 4.7%: low 3.40$, high 3.73$
Factors to consider:
- Total employees count: 69 (-43.0%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Operational and conduct risks, Product candidate safety issues, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.99$, 5.11$]
- 2026-12-31 to 2027-12-31 estimated range: [1.51$, 4.05$]
Financial Metrics affecting the CTMX estimates:
- Positive: with PPE of -103.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.91 <= 0.28
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: -14.39 < Investing cash flow per share per price, % of -10.20
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 65.32 > 63.63
Short-term CTMX quotes
Long-term CTMX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $101.21MM | $138.10MM | $76.20MM |
| Operating Expenses | $107.70MM | $113.11MM | $98.56MM |
| Operating Income | $-6.48MM | $25.00MM | $-22.36MM |
| Non-Operating Income | $9.81MM | $7.10MM | $5.23MM |
| R&D Expense | $77.68MM | $83.38MM | $68.73MM |
| Income(Loss) | $3.32MM | $32.09MM | $-17.13MM |
| Taxes | $3.89MM | $0.22MM | $0.24MM |
| Net Income(Loss)* | $-0.57MM | $31.87MM | $-17.37MM |
| Stockholders Equity | $-47.45MM | $-0.46MM | $99.01MM |
| Assets | $201.79MM | $120.53MM | $151.57MM |
| Operating Cash Flow | $-56.03MM | $-86.23MM | $-75.59MM |
| Capital expenditure | $0.84MM | $0.31MM | $0.22MM |
| Investing Cash Flow | $-150.67MM | $99.70MM | $-59.74MM |
| Financing Cash Flow | $30.23MM | $7.52MM | $110.45MM |
| Earnings Per Share** | $-0.01 | $0.38 | $-0.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.